Home » AstraZeneca Licenses Vanderbilt University’s Monoclonal Antibodies for COVID-19
AstraZeneca Licenses Vanderbilt University’s Monoclonal Antibodies for COVID-19
AstraZeneca has licensed six monoclonal antibodies from Vanderbilt University and plans to advance the most promising ones for prevention and treatment of COVID-19.
Monoclonal antibodies are synthesized versions of natural antibodies that may be able to neutralize the SARS-CoV-2 virus.
The company said it plans to begin a study of two antibodies as a combination treatment within the next two months.
Upcoming Events
-
07May
-
14May
-
30May